PMID- 35706821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 11
IP  - 5
DP  - 2022 May
TI  - Therapeutic potential of anti-miR29a in breast cancer patients with type 2 
      diabetes: an in vitro and xenograft mouse-model study.
PG  - 1285-1296
LID - 10.21037/tcr-22-824 [doi]
AB  - BACKGROUND: MicroRNAs (miRNAs) acting as tumour suppressors or oncogenes, known 
      as oncomiRs, are a promising new focus in targeted therapies for cancer. 
      Approximately 16% of breast cancer patients have pre-existing diabetes. Breast 
      cancer with type 2 diabetes mellitus (BDM) is provided with its unique biological 
      characteristics and clinical characteristics. This study primarily investigated 
      the therapeutic potential and regulatory mechanism of miR-29a in patients with 
      BDM. METHODS: The significance of miR-29a in BDM was analyzed by real-time 
      reverse transcriptase polymerase chain reaction (qRT-PCR) in breast tissues. A 
      cell model for BDM was established by using MDA-MB-231 cells cultured in 3T3-L1 
      adipocytes cultured with high levels of glucose and insulin. A type 2 diabetes 
      mellitus (T2DM) mouse model was induced in female BALB/c mice through a high-fat 
      diet plus low doses of streptozotocin (STZ). The xenograft mouse-model for BDM 
      was established on these T2DM mouse by using MDA-MB-231 cells. Then the 
      biological effects of miR-29a knockdown mediated by lentivirus-shRNAs on cell 
      proliferation, apoptosis, cell cycle, and migration were investigated. RESULTS: 
      Our results indicated that miR-29a was upregulated in patients with BDM, which 
      correlated with a worse prognosis. In human breast cancer cells, miR-29a 
      knockdown reduced cell proliferation and cell migration and invasion in BDM. In 
      the T2DM xenograft, miR-29a knockdown suppressed MDA-MB-231 cells tumorigenesis 
      and metastasis. We also demonstrated that miR-29a promoted BDM cell growth and 
      metastasis by targeting Sirtuin 1 (SIRT1). CONCLUSIONS: Our findings indicated 
      that anti-miR-29a inhibited cell proliferation and invasion in BDM by targeting 
      SIRT1. We believe anti-miR-29a may represent a novel therapeutic approach for the 
      management of patients with BDM.
CI  - 2022 Translational Cancer Research. All rights reserved.
FAU - Li, Zhihua
AU  - Li Z
AD  - Department of Breast Surgery, Third Hospital of Nanchang, Nanchang, China.
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Min, Liangliang
AU  - Min L
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Chen, Lu
AU  - Chen L
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Hu, Yangyang
AU  - Hu Y
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Luan, Wenjing
AU  - Luan W
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Li, Cong
AU  - Li C
AD  - Department of Breast Surgery, Third Hospital of Nanchang, Nanchang, China.
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Xiong, Qiuyun
AU  - Xiong Q
AD  - Department of Breast Surgery, Third Hospital of Nanchang, Nanchang, China.
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Huang, Kedi
AU  - Huang K
AD  - Key Laboratory of Breast Diseases in Jiangxi Province, Third Hospital of 
      Nanchang, Nanchang, China.
AD  - Orthopaedics Department, Third Hospital of Nanchang, Nanchang, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC9189168
OTO - NOTNLM
OT  - Anti-miR-29a
OT  - breast cancer
OT  - diabetes mellitus
OT  - sirtuin 1 (SIRT1)
OT  - target therapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tcr.amegroups.com/article/view/10.21037/tcr-22-824/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/06/17 06:00
MHDA- 2022/06/17 06:01
PMCR- 2022/05/01
CRDT- 2022/06/16 02:28
PHST- 2022/03/08 00:00 [received]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/06/16 02:28 [entrez]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/17 06:01 [medline]
PHST- 2022/05/01 00:00 [pmc-release]
AID - tcr-11-05-1285 [pii]
AID - 10.21037/tcr-22-824 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2022 May;11(5):1285-1296. doi: 10.21037/tcr-22-824.